XNAS · NCEL
+3.19% · +$0.1100 · Vol 6.0K
After hours · updated 16:00:00 ET
NewcelX Ltd. Ordinary Shares

NewcelX Ltd. Ordinary Shares

$3.56
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
NCEL
NewcelX Ltd. Ordinary Shares
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100
Veridion Score
BUY BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NCEL moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NCEL catalysts
About NewcelX Ltd. Ordinary Shares
Listed since
2021
Employees
4
Country
US

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.54
Day high
$3.75
Day low
$3.49
Previous close
$3.45
52W high
$7.29
-51.17% from high
52W low
$1.88
31% of range
Market cap
$18.6M
Beta
0.85
Shares out
5.4M
Volume
6K
0.22× rel vol
Avg volume
27.3K
VWAP
$3.58
Price history computed in-house
1W
+1.14%
1M
-8.83%
3M
+9.88%
YTD
+87.37%
SMA 50 $3.57 · below
SMA 200 Not reported · Not reported
52W position 31%

NCEL overview

Veridion Score
62
4 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NCEL.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NCEL Form 4 filings
Public disclosures

Congress activity in NCEL

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NCEL in the cached public ledger.

Federal contracts

NCEL contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NCEL in this window.
Lobbying spend

NCEL lobbying filings, year to date.

Registered lobbying filings matched to NewcelX Ltd. Ordinary Shares.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NCEL in this window.
Loading news for NCEL
Analyst ratings
Sovereign unlock shows live analyst consensus for NCEL.
Options
Sovereign unlock shows live options positioning for NCEL.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.